Category Archives: Patent case

AN UPDATE: India – Natco – Compulsory license

This is an update of Natco’s compulsory license application for Sorafenib and continuation of the earlier post. Controller of patent posted this CL opposition hearing on Jan 06, 2012. (DNA article). Bayer/patentee has sought for adjournment of this hearing (copy of … Continue reading

Posted in Daily interesting IP news, Patent case | Tagged , , , | Leave a comment

Madras High Court – Erlotinib patent infringement suits

[Business Line] [India Infoline] [Order] We are aware that Roche has filed patent infringement suit against some companies (Intas, Matrix) in Madras High Court which is related to Erlotinib and the patent No. 196774. Both of the suits and connected … Continue reading

Posted in Daily interesting IP news, Patent case | Tagged , , , , | Leave a comment

Presumption of patent validity in granting interim injunction

[Order] [SpicyIP] A granted patent can not be presumed to be valid. The presumption of patent validity is very less when defendant shows substantial doubts on violation of procedures in patent grant and credible challenge on patentibility and also when patent is granted recently. … Continue reading

Posted in Daily interesting IP news, Patent case, Uncategorized | Tagged , , | Leave a comment

Bayer Vs Controller of patents

[SpicyIP] [Order] Yesterday, a interesting news is posted in SpicyIP blog.  Bayer challenges ambiguity in statutory language of “prima facie case” of section 87(1). Controller has published Natco’s compulsory license as per section 87(1) as prima facie case made out (published on Aug 12th … Continue reading

Posted in Daily interesting IP news, Patent case | Tagged , , , | 1 Comment

Fosamprenavir – opposition – india

Indian patent journal of this week (Sep 16th, 2011) has a post grant opposition filed under section 25(2). Lupin has filed post grant opposition to 240930 (2210/Cal/1998) under section 25(2)  on June 08, 2011. The ‘930 patent seems to cover Fosamprenavir, is … Continue reading

Posted in Daily interesting IP news, Patent case | Tagged , , , , , , | Leave a comment

Yasmin patent revoked in Europe

[Fox business] EPO revokes EP1214076B1 patent relates to Formulation of Yasmin product and it is equivalent of US6787531 (Not updated in register Plus). This decision came from appeal filed by Hexal against Opposition board decision. The same patent’s equivalent (IN/PCT/2002/410/CHE) … Continue reading

Posted in Patent case | Tagged , , , | Leave a comment

India: Varenacline Patent revoked

Varenaciline is marketed by Pfizer world wide as Chandix or Champix. Varenaciline is marketed as tartarate salt form, this salt form is protected by US patent 6890927 and its indian equivalent is 204091 (863/MUMNP/2003). This ‘091 patent is opposed by Dr … Continue reading

Posted in Patent case | Tagged , , , , , | Leave a comment

Palonosetron-Opposition-India

A new pre grant opposition decision is published by patent office which is related to palonosetron. Application No: 1024/MUMNP/2005, Assignee: Helsinn Healthcare, Title: “Use of palonosetron treating postoperative nausea and vomiting“. This application is opposed by glenmark and Sun pharma. This … Continue reading

Posted in Patent case | Tagged , , , , , , | Leave a comment

Deferacirox-composition-pregrant oppoisition-india

A new pre grant opposition decision is uploaded in IPO site. Application NO: 593/CHENP/2005 is assigned to Novartis and Titled “Dispersible tablets comprising deferacirox”. This application is opposed by Cipla under 25(1). This application is refused under lack of inventive … Continue reading

Posted in Patent case | Tagged , , , | Leave a comment

Erlotinib-divisional-2018/CHE/2006-India

We aware that Erlotinib product patent is granted in India as 196774 (537/DEL/1996) and is is subject of many patent infringement cases filed at Delhi high court. Applicant has a divisional application (2018/CHE/2006) of ‘774 patent, which is pending at IPO Chennai. … Continue reading

Posted in Patent case | Tagged , , , | Leave a comment